 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
The Cost-Effectiveness of Testing HIV for Genetic Signs of Drug Resistance as a Guide to the Choice of Therapy
20 March 2001 | Volume 134 Issue 6 | Page S89
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness." It is in the 20 March 2001 issue of Annals of Internal Medicine (volume 134, pages 440-450). The authors are MC Weinstein, SJ Goldie, E Losina, CJ Cohen, JD Baxter, H Zhang, AD Kimmel, and KA Freedberg.
What is the problem and what is known about it so far?
Human immunodeficiency virus (HIV) interferes with the ability to fight infections. Therapy with combinations of anti-HIV drugs can reduce the amount of the virus in the blood and improve patient outcomes. Unfortunately, the virus can become resistant to the drugs, and the patient must then change to another combination. It is now possible to test the genes of the virus directly for signs of resistance to particular drugs (genotypic resistance testing). It is unknown whether the cost of these tests is worth the benefit.
Why did the researchers do this particular study?
To learn whether using genotypic resistance testing to guide the choice of anti-HIV drugs is worth the benefit.
Who was studied?
The researchers used computers to simulate what would happen to a hypothetical "virtual" group of patients with HIV infection.
How was the study done?
Using published data from previous studies, the researchers estimated the effect of using genotypic resistance testing in addition to doctors' judgment to guide the choice of anti-HIV drugs. They looked at 1) patients beginning anti-HIV drugs for the first time [primary resistance testing] and 2) patients in whom the first anti-HIV drug regimen had failed (secondary resistance testing). The researchers then explored what would happen over time depending on whether genotypic resistance testing was used, and they calculated how much each strategy would cost society for a given amount of benefit. Benefit was measured in quality-adjusted life-years (QALYs), a unit of measure that considers not only how long a person lives but also his or her quality of life during that time.
What did the researchers find?
If only about 4 of every 100 patients beginning their first anti-HIV drugs were infected with resistant virus, primary genotypic resistance testing would cost $69,000 per QALY gained. If 20 of every 100 had resistant virus, then primary resistance testing would cost $22,300 per QALY gained. Secondary resistance testing was estimated to cost about $17,000 per QALY gained. On the basis of these findings, and compared with many other accepted therapies, genotypic resistance testing can be considered cost-effective.
What were the limitations of the study?
This study was a computer simulation, so we cannot be sure what the results would be with actual patients.
What are the implications of the study?
Genotypic resistance testing of patients in whom an anti-HIV drug regimen has failed appears to be cost-effective. Genotypic resistance testing of patients beginning their first anti-HIV drug regimen may be cost-effective if the suspicion of resistance is high.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. J. Little, S. D. W. Frost, J. K. Wong, D. M. Smith, S. L. K. Pond, C. C. Ignacio, N. T. Parkin, C. J. Petropoulos, and D. D. Richman Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection J. Virol., June 1, 2008; 82(11): 5510 - 5518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy Med Decis Making, December 1, 2007; 27(6): 789 - 821. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Losina, R. P. Walensky, A. Geller, F. C. Beddingfield III, L. L. Wolf, B. A. Gilchrest, and K. A. Freedberg Visual Screening for Malignant Melanoma: A Cost-effectiveness Analysis Arch Dermatol, January 1, 2007; 143(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Paltiel, R. P. Walensky, B. R. Schackman, G. R. Seage III, L. M. Mercincavage, M. C. Weinstein, and K. A. Freedberg Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs Ann Intern Med, December 5, 2006; 145(11): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Walensky, M. C. Weinstein, H. E. Smith, K. A. Freedberg, and A. D. Paltiel Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral Med Decis Making, May 1, 2005; 25(3): 321 - 329. [Abstract] [PDF]
|
|
|
|
 |
|
 D. D. Richman Benefits and limitations of testing for resistance to HIV drugs J. Antimicrob. Chemother., April 1, 2004; 53(4): 555 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Katzenstein Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why? J Int Assoc Physicians AIDS Care (Chic Ill), October 1, 2003; 2(4): 140 - 146. [PDF]
|
|
|
|
|
|
J. M. Mrus, M. S. Yi, K. A. Freedberg, A. W. Wu, R. Zackin, H. Gorski, and J. Tsevat Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS Med Decis Making, September 1, 2003; 23(5): 414 - 421. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Korn, H. Reil, H. Walter, and B. Schmidt Quality Control Trial for Human Immunodeficiency Virus Type 1 Drug Resistance Testing Using Clinical Samples Reveals Problems with Detecting Minority Species and Interpretation of Test Results J. Clin. Microbiol., August 1, 2003; 41(8): 3559 - 3565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Huang, S. H. Eshleman, D. J. Brambilla, P. E. Palumbo, and J. W. Bremer Evaluation of the Editing Process in Human Immunodeficiency Virus Type 1 Genotyping J. Clin. Microbiol., July 1, 2003; 41(7): 3265 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Kuehne, U. Bethe, K. Freedberg, and S. J. Goldie Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness Arch Intern Med, December 9, 2002; 162(22): 2545 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Schackman, K. A. Freedberg, M. C. Weinstein, P. E. Sax, E. Losina, H. Zhang, and S. J. Goldie Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults Arch Intern Med, November 25, 2002; 162(21): 2478 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Hirsch HIV Drug Resistance -- A Chink in the Armor N. Engl. J. Med., August 8, 2002; 347(6): 438 - 439. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Phillips, D. L. Veenstra, E. Oren, J. K. Lee, and W. Sadee Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review JAMA, November 14, 2001; 286(18): 2270 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie and A. R. Levin Genomics in Medicine and Public Health: Role of Cost-effectiveness Analysis JAMA, October 3, 2001; 286(13): 1637 - 1638. [Full Text] [PDF]
|
|
|
|
|
|
A. Messori, S. Trippoli, M. Vaiani, J. Laurence, K. A. Freedberg, E. Losina, and S. J. Goldie The Cost Effectiveness of Antiretroviral Therapy for HIV Disease N. Engl. J. Med., July 5, 2001; 345(1): 68 - 69. [Full Text] [PDF]
|
|
|
|
 |
|
 Cost-Effectiveness of Resistance Testing AIDS Clinical Care, May 1, 2001; 2001(501): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Resistance Testing for HIV is Cost-Effective Journal Watch (General), March 23, 2001; 2001(323): 3 - 3. [Full Text]
|
|
|
|
|
|
M. S. Saag HIV Resistance Testing in Clinical Practice: A QALY-fied Success Ann Intern Med, March 20, 2001; 134(6): 475 - 477. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
